IONS Isis Pharmaceuticals: Bozor kapitallashuvining balans qiymatiga nisbati

Ionis Pharma (IONS) - korporativ logo

Ionis Pharmaceuticals (IONS) o'zining noyob RNA platformasi tufayli kamyob kasalliklar dori vositalari uchun monopol narxlardan foydalanadi. Biznes barqarorligi sog'liqni saqlash gigantlarining qo'llab-quvvatlashi va klinik sinovlar natijalariga asoslangan. Kitob qiymatiga nisbatan joriy bozor kapitalizatsiyasi ushbu bog'liqlikni tasdiqlaydi, bunda joriy daraja 16.50 ni tashkil etadi. Royalti to'lovlaridan tushadigan barqaror pul oqimi va kardiologiya sohasidagi ishlanmalar salohiyati uzoq muddatli qiymat o'sishini ta'minlaydi.

Isis Pharmaceuticals (IONS): Kapitallashuvning balans qiymatiga nisbati 04.07.2022dan 28.10.2026gacha

Ionis Pharmaceuticals, Inc. (IONS) moliyaviy va bozor koʻrsatkichlari kesimi

- narx va narxlar bo'yicha konsensus prognoz:
Narx grafigi Ionis Pharmaceuticals|IONS - Tahlilchilar median maqsadi
- bozor kapitallashuvi bo'yicha ma'lumotlar:
Bozor kapitallashuvi Ionis Pharma|IONS - Biznes qiymati
- balans kapitallashuvi bo'yicha ma'lumotlar:
Bitta aksiya uchun sof aktivlar Ionis|IONS - Buxgalteriya kapitallashuvi|Bozor kapitallashuvining balans qiymatiga nisbati ionispharma.com|IONS - Kompaniyaning umumiy aktivlari
- qarz va likvidlik bo'yicha ma'lumotlar:
Umumiy qarzning kapitalga nisbati Ionis Pharmaceuticals|IONS - Uzoq muddatli qarzdorlikning kapitalga nisbati|Qisqa muddatli qarzning o'z kapitaliga nisbati Ionis Pharma|IONS - Kompaniyaning umumiy yig'indi qarzi|Qarzning balans kapitallashuviga nisbati Ionis Pharma
Fundamental baholash:IONS, Ionis Pharmaceuticals
Ionis Pharma tomonidan chiqariladigan mahsulotlar

Ushbu koeffitsient Ionis Pharmaceuticals (IONS) bozor qiymatini uning sof aktivlariga solishtirib, kapitalning balans qiymatiga nisbatan haddan tashqari qimmat yoki arzon baholanganlik darajasini aniqlaydi. Narxning balans qiymatiga nisbati tendentsiyasini tahlil qilish orqali investorlar Ionis Pharmaceuticals (IONS) kompaniyasining Wainua preparatini to'g'ridan-to'g'ri sotuvga o'tishi va RNA terapiyalarini monetizatsiya qilish davridagi biznes barqarorligini baholaydilar, bunda aktivlar qiymatining o'sishi bozor optimizmini tasdiqlashi lozim.

Raqobatchilar tahlili

Tempus Labs - Bozor qiymatining balans qiymatiga nisbati|qiagen.com (QGEN) - Balans qiymatiga nisbatan bozor kapitallashuvi|Bozor kapitallashuvining balans qiymatiga nisbati Repligen (RGEN)|Kapitallashuvning balans qiymatiga nisbati RNA|Bozor qiymatining balans qiymatiga nisbati CRISPR Therapeutics Corp CRSP|Kapitallashuvning balans qiymatiga nisbati GeneDx Corp (WGS)|Bozor kapitallashuvining balans qiymatiga nisbati RARE (Ultragenyx Pharmaceutical)|Bozor kapitallashuvining balans qiymatiga nisbati beamtx.com BEAM|Bozor kapitallashuvining balans qiymatiga nisbati SRPT (Sarepta)|TWST: Balans qiymatiga nisbatan bozor kapitallashuvi|Bozor qiymatining balans qiymatiga nisbati TXG|NTLA (Intellia Corp) - Bozor qiymatining balans qiymatiga koeffitsiyenti|Bozor qiymatining balans qiymatiga nisbati Stoke Therapeutics (STOK)|Kapitallashuvning balans qiymatiga nisbati biolifesolutions.com|WVE (Wave Life Sciences Ltd.) - Bozor kapitallashuvining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor kapitallashuvi MAZE (Maze Therapeutics, Inc.)|Bozor qiymatining balans qiymatiga nisbati SION|PRME - Balans qiymatiga nisbatan bozor kapitallashuvi|Kapitallashuvning sof aktivlarga nisbati Taysha Gene Therapies (TSHA)|QURE: Balans qiymatiga nisbatan bozor qiymati|Bozor qiymatining balans qiymatiga nisbati MeiraGTx (MGTX)|REGENXBIO Inc (RGNX) - Sof aktivlarga nisbatan bozor kapitallashuvi|SLDB - Bozor kapitallashuvining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor qiymati Ocugen Pharma|Bozor kapitallashuvining balans qiymatiga nisbati PACB|Bozor kapitallashuvining balans qiymatiga nisbati BNTC (benitec.com)|Bozor qiymatining balans qiymatiga nisbati Design Therapeutics, Inc.|Rocket Pharma - Balans qiymatiga nisbatan bozor qiymati|FDMT: Bozor qiymatining balans qiymatiga nisbati|LXEO - Kapitallashuvning sof aktivlarga nisbati|KRRO: Bozor kapitallashuvining balans qiymatiga nisbati|editasmedicine.com (EDIT) - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati SLN|Kapitallashuvning sof aktivlarga nisbati ProQR Therapeutics NV|Codexis, Inc. - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga koeffitsiyenti Sangamo BioSciences SGMO|Kapitallashuvning sof aktivlarga nisbati NAUT (Nautilus Bio)|MGX - Bozor kapitallashuvining balans qiymatiga nisbati|Kapitallashuvning sof aktivlarga nisbati Precision BioSciences DTIL|GBIO - Bozor kapitallashuvining balans qiymatiga multiplikatori|Boundless Bio, Inc - Bozor kapitallashuvining balans qiymatiga nisbati|Exicure (XCUR) - Balans qiymatiga nisbatan bozor kapitallashuvi|Bozor kapitallashuvining balans qiymatiga nisbati IMNN|Kapitallashuvning sof aktivlarga nisbati RXi Pharmaceuticals|Bozor kapitallashuvining balans qiymatiga nisbati MBIO|Bozor kapitallashuvining balans qiymatiga nisbati RNAZ (transcodetherapeutics.com)|Bozor qiymatining balans qiymatiga nisbati Bionano Genomics BNGO|Applied DNA Corp - Bozor qiymatining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga nisbati BLUE (bluebird bio, Inc.)|IPA - Balans qiymatiga nisbatan bozor kapitallashuvi|Omega Therapeutics, Inc. - Bozor kapitallashuvining balans qiymatiga nisbati|OMIC (Singular Genomics Systems, Inc.) - Balans qiymatiga nisbatan bozor kapitallashuvi|Bozor qiymatining balans qiymatiga nisbati RGLS (Regulus Therapeutics Inc)|Bozor qiymatining balans qiymatiga koeffitsiyenti SYRS|Bozor qiymatining balans qiymatiga nisbati Telesis Bio, Inc. TBIO|Kapitallashuvning balans qiymatiga nisbati TCON (traconpharma.com)|Bozor qiymatining balans qiymatiga nisbati UBX